Pyrazinamide Resistance, Mycobacterium tuberculosis Lineage and Treatment Outcomes in San Francisco, California

Pyrazinamide (PZA) is a first line agent for the treatment of active tuberculosis. PZA is also considered a potent companion drug for newer regimens under development. There are limited data on the demographic, clinical, and pathogen characteristics of PZA resistant tuberculosis. Using a retrospecti...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	PloS one Ročník 9; číslo 4; s. e95645
Hlavní autoři:	Budzik, Jonathan M., Jarlsberg, Leah G., Higashi, Julie, Grinsdale, Jennifer, Hopewell, Phil C., Kato-Maeda, Midori, Nahid, Payam
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Public Library of Science 01.04.2014 Public Library of Science (PLoS)
Témata:	Antibiotics Antitubercular Agents - therapeutic use Biology and Life Sciences Clinical outcomes Comparative analysis Critical care Data processing Demographics Disease Disease resistance Drug resistance Drug resistance in microorganisms Drug therapy Epidemiology Health surveillance Hospitals Humans Infections Medical diagnosis Medicine Medicine and Health Sciences Microbial Sensitivity Tests Mycobacterium bovis Mycobacterium tuberculosis Mycobacterium tuberculosis - drug effects Mycobacterium tuberculosis - pathogenicity Patient outcomes Patients Pharmaceutical research Public health Pyrazinamide Pyrazinamide - pharmacology Pyrazinamide - therapeutic use Retrospective Studies San Francisco Statistical analysis Treatment Outcome Tuberculosis Tuberculosis - drug therapy Tuberculosis, Multidrug-Resistant - drug therapy San Francisco California Canada San Francisco California United States > US Quebec Canada
ISSN:	1932-6203, 1932-6203
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!